This article is more than 5 years old. Information may no longer be current.

Adverum begins next step of wet AMD gene therapy trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular degeneration, Adverum Biotechnologies announced in a press release.

The second cohort of the multicenter, open-label OPTIC trial is receiving an intravitreal injection with a dose of ADVM-022 of 2 × 10¹² vg per eye. Safety and tolerability of ADVM-022 at 24 weeks are the study’s primary endpoints.

“We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD. In the first cohort of patients, we have seen a robust preliminary anatomical response and no serious adverse events to date,” Aaron Osborne, MBBS, MRCOphth, Adverum chief medical officer, said in the release.